TPIV100 and Sargramostim for the Treatment of HER2 Positive, Stage II-III Breast Cancer in Patients With Residual Disease After Chemotherapy and Surgery
Status: RECRUITING
Study type: INTERVENTIONAL
Conditions: Breast Adenocarcinoma|Stage II Breast Cancer AJCC v6 and v7|Stage IIA Breast Cancer AJCC v6 and v7|Stage IIB Breast Cancer AJCC v6 and v7|Stage III Breast Cancer AJCC v7|Stage IIIA Breast Cancer AJCC v7|Stage IIIB Breast Cancer AJCC v7|Stage IIIC Breast Cancer AJCC v7
Interventions: BIOLOGICAL: Multi-epitope HER2 Peptide Vaccine TPIV100|BIOLOGICAL: Pertuzumab|OTHER: Placebo Administration|BIOLOGICAL: Sargramostim|BIOLOGICAL: Trastuzumab|BIOLOGICAL: Trastuzumab Emtansine
Sponsor: Academic and Community Cancer Research United
Collaborators: National Cancer Institute (NCI)